License Revenue was LENZ Therapeutics’s largest product and service line in fiscal 2025, bringing in $17.50M of $19.09M (92%).
| Product and Service | FY 2022 | FY 2025 |
|---|---|---|
| License Revenue | $15.00M | $17.50M |
| Product Sales, Net | — | $1.59M |
| Total | $15.00M | $19.09M |
LENZ Therapeutics brought in $19.09M from its two product and service lines in fiscal 2025, the year ended December 31, 2025. LENZ Therapeutics regrouped these lines after fiscal 2022, so the total does not compare directly with that year's $15.00M. License Revenue was the largest at $17.50M (91.7%), ahead of Product Sales, Net at $1.59M (8.3%).
LENZ Therapeutics began breaking out Product Sales, Net in fiscal 2025, when it brought in $1.59M.
LENZ Therapeutics (LENZ) reports its revenue by product and service. In fiscal 2025, License Revenue was its largest product and service line, bringing in $17.50M (91.7% of the total), followed by Product Sales, Net at $1.59M (8.3%).
License Revenue was LENZ Therapeutics' largest product and service line in fiscal 2025, bringing in $17.50M, or 91.7% of the $19.09M total across its two product and service lines.
Every figure comes from LENZ Therapeutics' annual financial filings, as reported. Each line keeps the name LENZ Therapeutics gives it, and years follow its fiscal calendar.
LENZ Therapeutics' revenue by product and service goes back to fiscal 2022, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.